Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis8 October 2018 Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome. The portfolio of Primer Capital now includes 10 projects from Russia, USA, Israel and France.
MatriSys Bioscience is currently completing the Phase I/IIa clinical trials of MSB-01 in the United States. The investments will be used for conducting clinical trials of Phase IIb and financing the company's development in the field of bacteriotherapy of other dermatological diseases.
Atopic dermatitis is a chronic recurrent disease, the clinical manifestations of which range from small inflammation sites near the knees and elbows to extensive lesions of more than 90% of the skin. Such heterogeneity does not allow for an accurate assessment of the global disease prevalence, but in the industrialized countries of Europe and North America it reaches 25%.
There are several hypotheses regarding the mechanism of the disease development, one of them relates to a disbalance of the skin microbiome and skin colonization with S. aureus. Staphylococcus aureus is found on the skin of 30-100% of patients with eczema, depending on the age, the severity of symptoms and method of detection. S. aureus has been proven to produce factors (δ-toxin, leukotoxins, hemolysins) that affect the pathogenesis of atopic dermatitis, exacerbate the disease state, and cause severe infectious complications if it enters the patient’s bloodstream through skin lesions.
Modern methods of atopic dermatitis management are aimed at alleviating the symptoms of the disease and preventing exacerbations, while in most cases the therapy of patients is based on the use of topical corticosteroids. Currently, there are no solutions on the market aimed at combating Staphylococcus aureus and restoring a healthy skin microbiome.
MSB-01 is a unique drug product developed by renowned world experts in the field of dermatology that offers a completely new therapeutic option for patients with atopic dermatitis. The drug has a high efficiency and an unprecedented safety profile, according to the results of pilot studies.
“Molecular bacteriotherapy is a new promising approach to the treatment of chronic skin diseases. According to the results of our scientific assessment and based on the high market demand for the development of new therapeutic options for the management of atopic dermatitis, this project has a high investment potential,” notes Elizaveta Rozhdestvenskaya, COO of Primer Capital.
“This investment from Primer Capital will allow MatriSys to continue the development of our microbiome-based therapeutics. MSB-01 is a development candidate which we believe will bring a new therapeutic modality to the treatment of atopic dermatitis. A recent survey of pediatric physicians has indicated a strong desire for non-steroidal topical microbiome solutions,” notes Mark S. Wilson, CEO of MatriSys Bioscience.
MatriSys Bioscience (founded in 2015) is a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions, which have a huge impact on patients’ quality of life, – Acne, Atopic Dermatitis, Rosacea, Psoriasis, and Skin Infections. MatriSys Bioscience’s Solution is to Re-Balance Skin Health by Integrating the Skin Microbiome and the Innate Immune System.
Back to the list